Kristin McDonald
Nurse Practitioner · Marion, ILNPI 1609401405
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 399 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 399 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- AbbVie$960
- AstraZeneca$820
- GSK$802
- Indivior Inc.$340
- Dexcom, Inc.$291
- plus $2K from 35 others
What the payments were for
- Food & beverage$6,469100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 65 | $1,090 |
| AbbVie | 69 | $960 |
| AstraZeneca | 51 | $820 |
| GSK | 55 | $802 |
| Indivior Inc. | 13 | $340 |
| Dexcom, Inc. | 16 | $291 |
| Novo Nordisk | 17 | $287 |
| Pfizer | 16 | $264 |
| Amgen | 19 | $234 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $124 |
| Merck | 5 | $103 |
| Exact Sciences | 6 | $97 |
| Vertex | 5 | $94 |
| Viiv Healthcare Company | 4 | $91 |
| Axsome Therapeutics, Inc. | 3 | $87 |
| Bayer | 5 | $87 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $54 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $48 |
| Mylan Specialty L.p. | 3 | $41 |
| Corcept Therapeutics | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Gilead | 2 | $38 |
| Abbott | 2 | $34 |
| Antares Pharma, Inc. | 2 | $34 |
| Sumitomo Pharma America, Inc. | 2 | $31 |
| Lundbeck LLC | 1 | $30 |
| Johnson & Johnson | 2 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Verona Pharma, Inc. | 1 | $27 |
| Braeburn Inc. | 1 | $26 |
| Boehringer Ingelheim | 2 | $25 |
| Sunovion Pharmaceuticals Inc. | 2 | $24 |
| Seqirus USA Inc | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $22 |
| Stryker | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| Alkermes, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Organon | 1 | $12 |
How this compares
$6,481 in reported general payments places this provider in the 95th percentile of 4,869 nurse practitioner providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 112 | $135,482 |
| TrulicityDulaglutide | 47 | $59,912 |
| EliquisApixaban | 45 | $54,490 |
| OzempicSemaglutide | 40 | $50,577 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $49,292 |
| MounjaroTirzepatide | 26 | $34,701 |
| LinzessLinaclotide | 24 | $26,628 |
| RybelsusSemaglutide | 14 | $25,358 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $13,344 |
| RestasisCyclosporine | 12 | $7,518 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $7,127 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $5,922 |
| SavellaMilnacipran Hcl | 12 | $5,597 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 245 | $5,362 |
| Atorvastatin Calcium | 274 | $3,296 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $25 | $135,482112 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,090 | $94,61373 claims |
| Novo NordiskOzempic, Rybelsus | $287 | $75,93554 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $802 | $62,63687 claims |
| PfizerEliquis | $264 | $54,49045 claims |
| AbbVieLinzess, Restasis, Savella | $960 | $39,74348 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,869 nurse practitioner providers in Illinois.
Other nurse practitioner in Marion
- Robin DaileyMarion$14K
- Deepa VallikatWest Dundee$332K
- Maria MalotoNaperville$135K
- Valerie LaroyOak Lawn$112K
- Jennifer LiebChampaign$109K
- Tanya MungerRockford$106K
- Erika VuckoChicago$76K
- Yvonna OldakerFlossmoor$74K
- Heather PiercePekin$72K
- Dara McKinleyEvanston$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.